Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Heron Therapeutics, Inc is a biotechnology business based in the US. Heron Therapeutics shares (HRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Heron Therapeutics employs 231 staff and has a trailing 12-month revenue of around USD$125.8 million.
Since the stock market crash in March caused by coronavirus, Heron Therapeutics's share price has had significant negative movement.
Its last market close was USD$18.36, which is 14.41% down on its pre-crash value of USD$21.45 and 91.25% up on the lowest point reached during the March crash when the shares fell as low as USD$9.6.
If you had bought USD$1,000 worth of Heron Therapeutics shares at the start of February 2020, those shares would have been worth USD$522.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$881.46.
|Latest market close||USD$18.36|
|52-week range||USD$9.6 - USD$26.81|
|50-day moving average||USD$15.0462|
|200-day moving average||USD$15.9903|
|Wall St. target price||USD$31.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.562|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||-0.33%|
|1 month (2020-10-30)||12.57%|
|3 months (2020-08-28)||29.30%|
|6 months (2020-05-29)||0.77%|
|1 year (2019-11-29)||-28.17%|
|2 years (2018-11-29)||-34.55%|
|3 years (2017-11-29)||8.32%|
|5 years (2015-11-27)||-38.35%|
|Revenue TTM||USD$125.8 million|
|Gross profit TTM||USD$-83,033,000|
|Return on assets TTM||-30.01%|
|Return on equity TTM||-63.01%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 17.0 million Heron Therapeutics shares held short by investors – that's known as Heron Therapeutics's "short interest". This figure is 10.5% up from 15.4 million last month.
There are a few different ways that this level of interest in shorting Heron Therapeutics shares can be evaluated.
Heron Therapeutics's "short interest ratio" (SIR) is the quantity of Heron Therapeutics shares currently shorted divided by the average quantity of Heron Therapeutics shares traded daily (recently around 891951.07273679). Heron Therapeutics's SIR currently stands at 19.11. In other words for every 100,000 Heron Therapeutics shares traded daily on the market, roughly 19110 shares are currently held short.
However Heron Therapeutics's short interest can also be evaluated against the total number of Heron Therapeutics shares, or, against the total number of tradable Heron Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heron Therapeutics's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Heron Therapeutics shares in existence, roughly 190 shares are currently held short) or 0.2283% of the tradable shares (for every 100,000 tradable Heron Therapeutics shares, roughly 228 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Heron Therapeutics.
Find out more about how you can short Heron Therapeutics stock.
We're not expecting Heron Therapeutics to pay a dividend over the next 12 months.
Heron Therapeutics's shares were split on a 1:20 basis on 13 January 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heron Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Heron Therapeutics shares which in turn could have impacted Heron Therapeutics's share price.
Over the last 12 months, Heron Therapeutics's shares have ranged in value from as little as $9.6 up to $26.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heron Therapeutics's is 1.6227. This would suggest that Heron Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.